Drug Profile


Alternative Names: SMAC-mimetic; TL-32711

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Princeton University
  • Developer Medivir AB; National Cancer Institute (USA); University of Pennsylvania
  • Class Amides; Antineoplastics; Indoles; Pyrrolidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myelomonocytic leukaemia; Colorectal cancer; Myelodysplastic syndromes; Ovarian cancer
  • Phase I/II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Hepatitis B; Solid tumours
  • Preclinical Legionella infections; Tuberculosis
  • Research HIV infections
  • No development reported Lymphoma; Pancreatic cancer

Most Recent Events

  • 18 Aug 2017 Phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Refractory metastatic disease) in USA (IV) (NCT02587962)
  • 29 Dec 2016 Medivir acquires birinapant from TetraLogic Pharmaceuticals
  • 02 Nov 2016 Medivir plans a phase I trial for Solid tumours (Combination therapy, Second-line therapy or greater)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top